Table 2 Patterns of disease recurrence and treatment of recurrent disease
Oesophageal/GOJ (n = 100) | Gastric (n = 47) | |
|---|---|---|
N (%) | N (%) | |
Time to relapse | ||
< 12 months | 53 (53 %) | 22 (47 %) |
12–24 months | 29 (29 %) | 12 (25 %) |
24–36 months | 12 (12 %) | 7 (15 %) |
> 36 months | 6 (6 %) | 6 (13 %) |
Relapse type | ||
Local | 7 (7 %) | 4 (9 %) |
Distant | 79 (79 %) | 37 (79 %) |
Both | 14 (14 %) | 6 (13 %) |
Site of relapsea | ||
Lymph nodes | 52 (52 %) | 14 (30 %) |
Anastomosis | 21 (21 %) | 10 (21 %) |
Peritoneum | 16 (16 %) | 18 (38 %) |
Liver | 18 (18 %) | 9 (19 %) |
Bone | 12 (12 %) | 4 (9 %) |
Abdominal wall | 3 (3 %) | 5 (11 %) |
Lung | 10 (10 %) | 2 (4 %) |
Brain | 10 (10 %) | 0 (0 %) |
Mediastinum | 9 (9 %) | 1 (2 %) |
Other | 8 (8 %) | 5 (11 %) |
Elevated tumour markers at relapse | ||
Yes | 63 (63 %) | 24 (51 %) |
No | 24 (24 %) | 16 (34 %) |
Unknown | 13 (13 %) | 7 (15 %) |
Symptoms at time of relapse | ||
Yes | 67 (67 %) | 34 (72 %) |
How relapse was first detected in asymptomatic patients | (n = 33) | (n = 12) |
Routine tumour markers | 22 (67 %) | 4 (33 %) |
Routine CT | 6 (18 %) | 4 (33 %) |
Concurrent routine CT/ markers | 1 (3 %) | 3 (25 %) |
Endoscopy | 2 (6 %) | 1 (8 %) |
Other | 2 (6 %) | 0 (0 %) |
ECOG performance status at relapse | ||
0 | 12 (12 %) | 3 (6 %) |
1 | 13 (13 %) | 7 (15 %) |
2 | 4 (4 %) | 2 (4 %) |
3–4 | 8 (8 %) | 4 (9 %) |
Unknown | 63 (63 %) | 31 (66 %) |
Further treatment for recurrent disease | ||
Yes | 72 (72 %) | 22 (47 %) |
Type of treatment for recurrent diseaseb | ||
Chemotherapy | 63 (88 %) | 19 (86 %) |
Radiotherapy | 21 (29 %) | 3 (14 %) |
Chemoradiotherapy | 1 (1 %) | 0 (0 %) |
Surgery | 5 (7 %) | 1 (5 %) |